thrombomodulin

**Structure/location:** Transmembrane glycoprotein expressed on the luminal surface of vascular endothelium (most abundant in capillaries and small vessels). Soluble forms circulate and serve as a marker of endothelial injury.

**Mechanism:** 1. Thrombin (factor IIa) binds thrombomodulin on endothelial cells. 2. The thrombin–thrombomodulin complex loses its procoagulant activity: it no longer cleaves fibrinogen to fibrin, activates platelets (PAR-1), or activates factors V, VIII, and XI. 3. The complex gains the ability to activate **protein C**, a process enhanced by the **endothelial protein C receptor (EPCR)**. 4. **Activated protein C (APC)**, with **protein S** as cofactor, proteolytically inactivates **factors Va and VIIIa**. This reduces thrombin generation (negative feedback). 5. The complex also activates TAFI (thrombin-activatable fibrinolysis inhibitor) at higher concentrations, which has an antifibrinolytic effect. This is a more advanced point.

**Clinical significance and associations:** - **Factor V Leiden (R506Q):** Factor Va is resistant to cleavage by APC, which causes APC resistance. It is the most common inherited thrombophilia and causes venous thromboembolism (DVT/PE, cerebral venous thrombosis). The aPTT-based APC resistance assay is the screening test. - **Protein C or S deficiency:** Hypercoagulable state. Warfarin-induced skin necrosis can occur on initiation because protein C has a short half-life (about 8 hours) and falls before the other vitamin K-dependent factors, producing a transient hypercoagulable state. Neonatal purpura fulminans occurs in homozygous deficiency. - **Sepsis/DIC:** Inflammatory cytokines (TNF-α, IL-1) downregulate thrombomodulin and EPCR on endothelium, which impairs protein C activation and promotes microvascular thrombosis. Drotrecogin alfa (recombinant APC) was withdrawn after it failed to show benefit. Recombinant soluble thrombomodulin (ART-123) is used in DIC in Japan. - **Endothelial injury markers:** Elevated soluble thrombomodulin reflects endothelial damage (for example in vasculitis, diabetes, and sepsis). - **Thrombomodulin and hemolytic uremic syndrome:** Complement-mediated (atypical) HUS has been linked to THBD mutations, because thrombomodulin also helps regulate complement (it enhances factor I-mediated inactivation of C3b).

**Pharmacology tie-ins:** Heparin works via antithrombin, whereas thrombomodulin/protein C works through a separate natural anticoagulant pathway. Dabigatran and argatroban directly inhibit thrombin. Warfarin reduces synthesis of vitamin K-dependent factors II, VII, IX, X, and proteins C and S.

**High-yield memory aid:** "Thrombomodulin turns thrombin from a clot-maker into a clot-breaker (via protein C)."

**Natural anticoagulant summary:** Antithrombin (inhibits IIa, Xa, and others, potentiated by heparin), Protein C/S + thrombomodulin (inactivate Va/VIIIa), and tissue factor pathway inhibitor (TFPI; inhibits the TF–VIIa complex and Xa).